Wolverine Asset Management’s Estrella Immunopharma Warrant ESLAW Stock Holding History

Wolverine Asset Management’s Portfolio ESLAW Stock Details ESLAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,191	Closed	-$113	–	1726
2025 Q3	$113	Hold	2,191	–	–	﹤0.01%	1566
2025 Q2	$104	Buy	+2,191	New	+$110	﹤0.01%	1568
2025 Q1	–	Sell	-3,256	Closed	-$299	–	1630
2024 Q4	$299	Sell	3,256 -1,047	-24%	-$89	﹤0.01%	1562
2024 Q3	$276	Sell	4,303 -1,400	-25%	-$114	﹤0.01%	1590
2024 Q2	$393	Hold	5,703	–	–	﹤0.01%	1589
2024 Q1	$378	Hold	5,703	–	–	﹤0.01%	1578
2023 Q4	$171	Buy	+5,703	New	+$444	﹤0.01%	1716

Other funds holding ESLAW

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

LCM

Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return

Wolverine Asset Management's ESLAW Position: Q4 2025 in Review

Wolverine Asset Management sold out of Estrella Immunopharma Warrant (ESLAW) in Q4 2025, closing a stake of 2,191 shares — an estimated $113 sold.

Wolverine Asset Management first reported a position in ESLAW in Q4 2023 and held it in 7 quarters. The position peaked at $393 in Q2 2024. 9 funds tracked by Wall St. Rank hold ESLAW as of Q4 2025.

Wolverine Asset Management reported no remaining Estrella Immunopharma Warrant position as of Q4 2025 after selling out during the quarter.
Wolverine Asset Management sold 2,191 Estrella Immunopharma Warrant shares in Q4 2025, an estimated $113.
Wolverine Asset Management first reported a position in Estrella Immunopharma Warrant in Q4 2023 and held it in 7 quarters.
Wolverine Asset Management's Estrella Immunopharma Warrant position peaked at $393 in Q2 2024.
9 funds tracked by Wall St. Rank held Estrella Immunopharma Warrant as of Q4 2025.

Based on Wolverine Asset Management's 13F filing for Q4 2025, filed 2 Feb 2026.